Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis
Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …
regulating tumorigenesis and cell survival and may be important in the development and …
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A …
WZ Zhong, KN Chen, C Chen, CD Gu… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
K Uchibori, N Inase, M Araki, M Kamada, S Sato… - Nature …, 2017 - nature.com
Osimertinib has been demonstrated to overcome the epidermal growth factor receptor
(EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine …
(EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine …
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
A new approach to predict progression-free survival in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy
Purpose: We established a CT-derived approach to achieve accurate progression-free
survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter …
survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter …
Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized …
B Han, B Jin, T Chu, Y Niu, Y Dong, J Xu… - … journal of cancer, 2017 - Wiley Online Library
To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations,
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
HY Tu, EE Ke, JJ Yang, YL Sun, HH Yan, MY Zheng… - Lung Cancer, 2017 - Elsevier
Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …
Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta …
H Liu, Y Wu, T Lv, Y Yao, Y Xiao, D Yuan, Y Song - PLoS one, 2013 - journals.plos.org
Background The aim of this study was to assess the role of skin rash in predicting the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
[HTML][HTML] Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization
CI Selinger, TM Rogers, PA Russell, S O'toole, PY Yip… - Modern pathology, 2013 - Elsevier
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer
(NSCLC) define a molecular subgroup of tumors characterized clinically by sensitivity to ALK …
(NSCLC) define a molecular subgroup of tumors characterized clinically by sensitivity to ALK …